Current Editions

Phase II data suggest some sporadic ALS cases are SOD1-driven, but mixed all-comer results make patient stratification critical in Phase III

CSF p-tau-217 fell sharply, but the discontinued mAb had only a modest effect on tau PET and none on spread to new brain regions

Korean biotech is punching above its weight with first-in-class programs and Western deals

Zenkuda meets in two Phase IIIs, ending the company’s four-year struggle to show late-stage opthlamic efficacy

U.K. biotech’s platform identifies small molecules that can shift disease-driving gene networks toward a healthier state

mRNA expression data suggest little additional efficacy to be gained from higher doses of INHBE-targeted WVE-007

CHMP recommends two FDA-approved therapies for extended-stage small cell lung cancer but rebuffs expanded label for Vanda’s Hetlioz in Smith-Magenis syndrome

Plus: New ways to improve delivery vectors, and translational innovations from cancer companies

Republican senator advocates restrictions that could limit U.S. patients’ access to therapies, restrict Chinese companies’ access to U.S. market

Deal in the works to add BCMA-targeting T cell engager to Belgian biotech’s thin pipeline, as its partner commits nearly $1.7B up front to buy NewCo

Plus: Gilgamesh spinout, Cohen’s Oryon, Neion draw cash; Ysios’ company creation fund; Apogee’s upsized offering; and more